May 16, 2019
Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
May 16, 2019
Charles River Laboratories Invests in Resero Analytics™
Access to Resero’s TurboToxicology™ will provide faster delivery of high-quality toxicology reports WILMINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CRL&src=ctag" target="_blank"gt;$CRLlt;/agt; lt;a href="https://twitter.com/hashtag/LIFEatCRL?src=hash" target="_blank"gt;#LIFEatCRLlt;/agt;–Charles…
May 16, 2019
High-Throughput Surveillance Study on Antibiotic Resistance Using the Automated SmartChip™ System
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is proud to announce that…
May 16, 2019
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
– Company Enters into Commercial Supply Agreement for AR101 – BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company…
May 16, 2019
OSSIO Announces U.S. Launch and First Commercial Use of the New OSSIOfiberTM Bone Pin for Hammertoe Correction
New Category Offers Surgeons Strong, Secure Fixation and “Biologically Friendly” Approach to Restoring Patient Stability and Mobility with No Permanent…
May 16, 2019
Certara Appoints Dr. William F. Feehery as Chief Executive Officer
PRINCETON, N.J.–(BUSINESS WIRE)–Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, announced today…
May 16, 2019
ImaginAb enrolls metastatic cancer patients for second phase testing CD8 T-cell ImmunoPET imaging agent
ImaginAb has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.
May 16, 2019
Testing Pradaxa vs acetylsalicylic acid for preventing recurrent stroke misses its goal: Boehringer Ingelheim
Boehringer Ingelheim’s the trial did not meet its primary endpoint, which was to show aclinically significant difference between dabigatran etexilate and ASAon reducing the risk of a recurrent stroke among post-stroke patientswith ESUS.
May 16, 2019
Entrectinib shrank tumours ORR in all children and adolescents: Roche study
Roche study showed entrectinib shrank tumours (objective response rate; ORR) in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours (11 of 11 patients), including two patients achieving a complete response.
May 16, 2019
Pharming Group net profit up for Q1 2019
Revenues increased approximately 19.5% to €35.2 million, compared with €29.5 million during the same period last year.